D. Boral says Hoth findings highlight HT-001 potential to ‘revolutionize’ care

After Hoth Therapeutics (HOTH) announced interim results from its Phase 2a CLEER-001 trial evaluating HT-001, a treatment for skin toxicities caused by Epidermal Growth Factor Receptor Inhibitors, D. Boral Capital noted that the open-label trial reported 100% of patients achieving the primary efficacy endpoint, which the analyst argues “highlight HT-001’s potential to revolutionize care for patients facing debilitating side effects from cancer treatments.” The firm maintains a Buy rating and $5 price target on Hoth shares.